Wed, Jul 23, 2014, 2:46 PM EDT - U.S. Markets close in 1 hr 14 mins

Recent

% | $
Click the to save as a favorite.

Momenta Pharmaceuticals Inc. Message Board

  • ding_king2000 ding_king2000 Apr 30, 2013 8:55 AM Flag

    Total revenue for the first quarter of 2013 was $7.6 million (including product revenue of $5.4 million), compared to $24.2 million (including product revenue of $22.0 million) for the same period in 2012. The decrease in product revenue of $16.6 million was principally due to a change in the contractual basis of Momenta's earned enoxaparin product revenues following the January 2012 launch of a competitor's generic Lovenox(R)

    This is a disaster, imho..

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Try again.

      {{Cash at 3/31/13 (including $20M restricted cash) was $344.2M, and cash-usage guidance for 2013 remains $20-24 per quarter or $80-90M for the year. The one notable clinical change is that the M402 phase-1/2 trial in pancreatic cancer will now include Abraxane + Gemzar as the baseline therapy (rather than Gemzar alone); the timeline for finishing the phase-1 (open-label) portion of the trial has been pushed back to 1H14 from the prior guidance of 1H13.}}

 
MNTA
11.4606+0.1406(+1.24%)2:46 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.